In addition to public funding, obtained through the call for tenders of the national “Grand loan”, this project is based on multiple funds. Most of these are provided by institutional partners, including Marseilles’ hospitals (AP-HM), Aix-Marseilles University, the Research Institute for Development (IRD, headquartered in Marseilles, including 3 mixed units), INSERM, CNRS, the School of High Studies in Public Health (EHESP) and the Blood French Establishment (EFS), the Health Services of the Army (SSA), the University Hospital Centres (CHUs) of Montpellier, Nimes, Nice, and the Universities of Montpellier 1, Montpellier 2, and Nice-Sophia-Antipolis.
Some large national industries in the field of infectious diseases and microbiology are also part of the project (Institut Mérieux, Sanofi Aventis, Cerba European Lab, IRT Lyon, Qiagen) as well as local companies (Galderma, Consortium MediHandtrace, I2a), the Crédit Coopératif, which already supported the Infectiopôle Sud Foundation, and the Caisse d’Epargne.
Local authorities, including the City of Marseilles, the county council (Conseil Général of Bouches-du-Rhône) and the regional council (Conseil Regional of Provence Côte d’Azur), which already supported the Infectiopôle Sud Foundation, are in commitment process.
A partnership with the largest French ship-owner CMA-CGM is also considered as part of travel medicine, which is often infectious and can be contagious.
